Praxis für Hämatologie und Onkologie

Recent papers from Praxis für Hämatologie und Onkologie

1. Circulating tumor DNA in body fluids for molecular characterization of cancers beyond tissue and bloodiScience · 2026
2. The impact of a nurse navigation program on health, economic and medical outcomes of cancer patients in Saxony – a multicenter, prospective, randomized controlled trialResearch in Health Services & Regions · 2026
3. Patient and Healthcare Provider Satisfaction With Subcutaneous Versus Intravenous Administration of Daratumumab in Combination With Lenalidomide and Dexamethasone as First‐Line Treatment in Patients With Newly Diagnosed Non‐Transplant Eligible Multiple Myeloma: Final Results of the MYLENE StudyEuropean Journal Of Haematology · 2026
4. Time to subsequent therapy (TTST) as an endpoint in clinical studies: development of standardized documentation of subsequent therapy through systematic literature review, expert interviews, and Delphi surveyJournal of Cancer Research and Clinical Oncology · 2026
5. Clinical Relevance of Post-Treatment Circulating Tumor DNA Detection in Early Breast Cancer Using a Tissue-Free Epigenomic Assay: A 2-Year Landmark AnalysisJCO Precision Oncology · 2026
6. BrECADD in three days: Implementation of a condensed intensive first‐line regimen in Hodgkin lymphomaBritish Journal of Haematology · 2026
7. Prospective, longitudinal oncology registries enabling advanced real-world evidence: the iOMEDICO experienceESMO Real World Data and Digital Oncology · 2026
8. Efficacy of a Decision‐Making Aid About Homeopathy in Patients With Cancer: A Single‐Arm, Pre–Post Observational StudyHealth Science Reports · 2026
9. Real-World Evidence for Oncology Patients With Rare NTRK Gene Fusions: Final Results From the German Multicenter Patient Cohort Study REALTRKJCO Precision Oncology · 2026
10. Clinical Course, Viral Load, and (Sub)Type of Influenza in Hospitalized Children in Southern GermanyJournal of Medical Virology · 2026
11. Surgical axillary intervention after neoadjuvant systemic therapy (NST) for early-stage breast cancer – Clinical significance of micrometastases: Data from five neoadjuvant studiesThe Breast · 2026
12. Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trialThe Lancet · 2026
13. Immunostimulatory functions of membrane-bound and exported heat shock protein 702026
14. Ibrutinib in early stage CLL: Genetic risk factors and treatment outcome in the GCLLSG CLL12 trialBlood · 2026
15. Prophylactic Anakinra to Prevent Neurotoxicity After CAR T-Cell Therapy in Aggressive B-Cell Lymphomas: A Single-Center Real-World Experience.2026
16. IGLV3‐21 R110 and ibrutinib treatment: Results from the double‐blind, randomized, placebo‐controlled GCLLSG CLL12 trial in early‐stage CLLHemaSphere · 2026
17. Scalp Cooling as a Biopsychosocial Intervention in Patients Receiving Highly Alopecia-Inducing Chemotherapy: Prospective Single-Arm StudyJMIR Cancer · 2026
18. Disease-free survival (DFS) and time to recurrence (TTR) with circulating tumor (ct) DNA–based decision for adjuvant treatment in colon cancer stage II (CIRCULATE): An AIO (KRK-0217)/ABCSG trial.Journal of Clinical Oncology · 2026
19. Adherence to Hepatocellular Carcinoma Surveillance Guidelines Among People with HIV and Chronic HBV InfectionClinical Infectious Diseases · 2026
20. Chemotherapy for patients with circulating tumour DNA positive, stage II colon cancer (CIRCULATE) – an AIO / ABCSG trialAnnals of Oncology · 2026